Determining how a cancer patient is responding to chemotherapy is currently challenging to assess. Rna Diagnostics, a Laurentian University spinoff company, has secured seed funding from iGan Partners and BDC Capital through its Bridge Financing Program to develop an innovative RNA disruption assay (RDA) diagnostic technology to help oncologists assess the efficacy of chemotherapy treatment early.
The RDA technology will help tailor treatments to an individual’s unique response, independent of cancer type or therapy, which means ineffective doses and lost time can be avoided if a patient’s tumor is not responding to treatment.
The investment will provide critical funding that supports the completion of clinical trials and brings the technology to market that will help improve cancer treatments and quality of life for patients in northern Ontario and around the world.
For more information, visit Laurentian University.
